The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
||||||||||||||||
| COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
| VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
| NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
| Aclaris Therapeutics | Common | 00461U105 | 28,859 | 1,647,214 | SH | SOLE | 1,647,214 | 0 | 0 | ||
| Agile Therapeutics, Inc. | Common | 00847L100 | 3,891 | 1,513,975 | SH | SOLE | 1,513,975 | 0 | 0 | ||
| Aimmune Therapeutics, Inc. | Common | 00900T107 | 9,768 | 306,872 | SH | SOLE | 306,872 | 0 | 0 | ||
| Akari Therapeutics Plc | ADR | 00972G108 | 629 | 345,850 | SH | SOLE | 345,850 | 0 | 0 | ||
| Amyris, Inc. | Common | 03236M200 | 18,911 | 2,826,711 | SH | SOLE | 2,826,711 | 0 | 0 | ||
| Apellis Pharmaceuticals, Inc. | Common | 03753U106 | 32,233 | 1,457,834 | SH | SOLE | 1,457,834 | 0 | 0 | ||
| Arrowhead Pharmaceuticals Inc | Common | 04280A100 | 13,699 | 1,900,000 | SH | SOLE | 1,900,000 | 0 | 0 | ||
| Ascendis Pharma | ADR | 04351P101 | 141,711 | 2,166,832 | SH | SOLE | 2,166,832 | 0 | 0 | ||
| Aurinia Pharmaceuticals Inc. | Common | 05156V102 | 6,297 | 1,213,290 | SH | SOLE | 1,213,290 | 0 | 0 | ||
| Biohaven Pharmaceutical Holding Company Ltd | Common | G11196105 | 52,796 | 2,049,545 | SH | SOLE | 2,049,545 | 0 | 0 | ||
| BioPharmX Corporation | Common | 09072X101 | 3,726 | 16,128,515 | SH | SOLE | 16,128,515 | 0 | 0 | ||
| Codexis, Inc. | Common | 192005106 | 33,603 | 3,054,825 | SH | SOLE | 3,054,825 | 0 | 0 | ||
| Cymabay Therapeutics Inc | Common | 23257D103 | 10,392 | 800,000 | SH | SOLE | 800,000 | 0 | 0 | ||
| Eiger BioPharmaceuticals | Common | 28249U105 | 17,644 | 1,791,257 | SH | SOLE | 1,791,257 | 0 | 0 | ||
| Foamix Pharmaceuticals Ltd. | SHS | M46135105 | 4,386 | 855,000 | SH | SOLE | 855,000 | 0 | 0 | ||
| Genocea Biosciences Inc | Common | 372427104 | 8,589 | 8,180,000 | SH | SOLE | 8,180,000 | 0 | 0 | ||
| Homology Medicines, Inc. | Common | 438083107 | 21,687 | 1,159,742 | SH | SOLE | 1,159,742 | 0 | 0 | ||
| Kadmon Holdings (KDMN) | Common | 48283N106 | 14,167 | 3,333,333 | SH | SOLE | 3,333,333 | 0 | 0 | ||
| Kala Pharmaceuticals, Inc. | Common | 483119103 | 16,511 | 1,043,020 | SH | SOLE | 1,043,020 | 0 | 0 | ||
| KalVista Pharmaceuticals, Inc. | Common | 483497103 | 2,847 | 300,325 | SH | SOLE | 300,325 | 0 | 0 | ||
| Madrigal Pharmaceuticals Inc | Common | 558868105 | 3,179 | 27,220 | SH | SOLE | 27,220 | 0 | 0 | ||
| Menlo Therapeutics | Common | 586858102 | 150,742 | 4,011,236 | SH | SOLE | 4,011,236 | 0 | 0 | ||
| Nabriva Therapeutics Plc | SHS | G63637105 | 20,493 | 4,074,190 | SH | SOLE | 4,074,190 | 0 | 0 | ||
| Regenxbio Inc. | Common | 75901B107 | 4,907 | 164,403 | SH | SOLE | 164,403 | 0 | 0 | ||
| Selecta Biosciences, Inc. | Common | 816212104 | 11,405 | 1,119,189 | SH | SOLE | 1,119,189 | 0 | 0 | ||
| Sierra Oncology, Inc | Common | 82640U107 | 5,047 | 2,438,270 | SH | SOLE | 2,438,270 | 0 | 0 | ||
| Soleno Therapeutics, Inc. | Common | 834203200 | 7,313 | 4,033,534 | SH | SOLE | 4,033,534 | 0 | 0 | ||
| Soleno Therapeutics, Inc. | Warrant | 834203135 | 23 | 188,772 | SH | SOLE | 188,772 | 0 | 0 | ||
| Strongbridge Biopharma plc | SHS USD | G85347105 | 16,975 | 1,918,132 | SH | SOLE | 1,918,132 | 0 | 0 | ||
| Sunesis Pharmaceuticals, Inc. | Common Par | 867328700 | 532 | 195,474 | SH | SOLE | 195,474 | 0 | 0 | ||
| Trevena, Inc. | Common | 89532E109 | 2,834 | 1,728,000 | SH | SOLE | 1,728,000 | 0 | 0 | ||
| Verona Pharma Plc | ADS | 925050106 | 29,859 | 1,492,951 | SH | SOLE | 1,492,951 | 0 | 0 | ||
| Zai Lab LTD | ADR | 98887Q104 | 6,059 | 283,787 | SH | SOLE | 283,787 | 0 | 0 | ||
| Zogenix, Inc. | Common | 98978L204 | 4,205 | 105,000 | SH | SOLE | 105,000 | 0 | 0 | ||